NeuroSense Locks Alzheimer's Trial Data, Results Due Q1 2026
Ticker: NRSNW · Form: 6-K · Filed: Dec 8, 2025 · CIK: 1875091
Sentiment: neutral
Topics: clinical-trial-update, alzheimers, drug-development
TL;DR
NeuroSense locked its Alzheimer's trial data, Q1 2026 results incoming. Big news for PrimeC.
AI Summary
NeuroSense Therapeutics Ltd. announced on December 8, 2025, that the database for its Phase 2 clinical trial of PrimeC in Alzheimer's disease, the RoAD study, has been locked. This milestone allows for final statistical analyses, with topline results anticipated in the first quarter of 2026. The company is based in Herzliya, Israel.
Why It Matters
The database lock is a critical step towards revealing the efficacy of PrimeC for Alzheimer's disease, potentially impacting future treatment options and the company's stock.
Risk Assessment
Risk Level: medium — Clinical trial results are inherently uncertain and can significantly impact a biotechnology company's valuation.
Key Numbers
- Q1 2026 — Topline Results (Expected timeframe for the release of results from the RoAD study)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report and company developing PrimeC
- PrimeC (drug) — Investigational drug for Alzheimer's disease
- RoAD study (clinical_trial) — Name of the Phase 2 clinical trial for PrimeC
- Alzheimer's disease (disease) — Indication being studied for PrimeC
- 11 HaMenofim Street, Building B Herzliya 4672562 Israel (address) — Principal executive office address
FAQ
What is the significance of locking the database for the RoAD study?
Locking the database signifies that all clinical data for the RoAD study has been collected and cleaned, allowing for final statistical analyses to commence.
When are the topline results for the RoAD study expected?
Topline results for the RoAD study are expected in the first quarter of 2026.
What is the primary indication for PrimeC in this trial?
PrimeC is being tested for Alzheimer's disease in the RoAD study.
What type of trial is the RoAD study?
The RoAD study is a proof-of-concept, Phase 2 clinical trial.
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 14.1 · Accepted 2025-12-08 08:00:21
Filing Documents
- ea0268801-6k_neuro.htm (6-K) — 12KB
- 0001213900-25-118962.txt ( ) — 13KB
Forward-Looking Statements
Forward-Looking Statements This Report on Form 6-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking control. For example, this Report on Form 6-K states that the topline results for the RoAD study is expected in the first quarter of 2026. In fact, the results may be delayed for various reasons, including those included in the Company’s Annual Report on Form 20-F, and it may be determined that additional data is required. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: December 8, 2025 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2